Embecta (NASDAQ:EMBC) Reaches New 52-Week Low – Time to Sell?

Embecta Corp. (NASDAQ:EMBC) reached a new 52-week low on Wednesday . The company traded as low as $8.72 and last traded at $8.7990, with a volume of 49547 shares. The stock had previously closed at $8.91.

Analyst Ratings Changes

A number of research firms recently commented on EMBC. Wall Street Zen raised Embecta from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Weiss Ratings reissued a “hold (c-)” rating on shares of Embecta in a research note on Wednesday, January 21st. Finally, BTIG Research reaffirmed a “buy” rating and set a $25.00 price target on shares of Embecta in a research note on Friday, February 6th. One investment analyst has rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Embecta presently has a consensus rating of “Hold” and a consensus target price of $18.50.

Embecta Stock Performance

The company has a market capitalization of $519.06 million, a price-to-earnings ratio of 3.70 and a beta of 1.10. The company has a fifty day simple moving average of $10.67 and a two-hundred day simple moving average of $12.48.

Embecta (NASDAQ:EMBC) last announced its quarterly earnings data on Thursday, February 5th. The company reported $0.71 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.04. The business had revenue of $261.20 million during the quarter, compared to the consensus estimate of $258.07 million. Embecta had a negative return on equity of 26.66% and a net margin of 12.92%.The business’s revenue for the quarter was down .3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.65 earnings per share. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. As a group, analysts expect that Embecta Corp. will post 2.85 EPS for the current year.

Embecta Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 17th. Shareholders of record on Friday, February 27th were issued a $0.15 dividend. The ex-dividend date was Friday, February 27th. This represents a $0.60 annualized dividend and a yield of 6.8%. Embecta’s payout ratio is 25.32%.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of EMBC. Royal Bank of Canada boosted its position in shares of Embecta by 38.3% in the first quarter. Royal Bank of Canada now owns 18,201 shares of the company’s stock worth $232,000 after acquiring an additional 5,036 shares during the last quarter. AQR Capital Management LLC increased its position in Embecta by 3.7% during the first quarter. AQR Capital Management LLC now owns 225,641 shares of the company’s stock worth $2,738,000 after purchasing an additional 8,109 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Embecta by 2.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock worth $629,000 after purchasing an additional 1,159 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Embecta by 4.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 172,173 shares of the company’s stock worth $2,195,000 after purchasing an additional 7,894 shares during the period. Finally, Jane Street Group LLC raised its stake in Embecta by 224.0% during the first quarter. Jane Street Group LLC now owns 132,688 shares of the company’s stock worth $1,692,000 after purchasing an additional 91,729 shares during the period. 93.83% of the stock is currently owned by hedge funds and other institutional investors.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.